ALLARITY THERAPEUTICS
Allarity Therapeutics is a biopharmaceutical company that develops oncology products and drugs for the personalized treatment of cancer. The company utilizes drug response predictor technology to refine patient selection and improve clinical outcomes. Its product pipeline includes Dovitinib, a pan-tyrosine kinase inhibitor for renal cell carcinoma (RCC), Stenoparib (2X-121), a dual PARP inhibitor, and Tankyrase Inhibitor for ovarian cancer; IXEMPRA (Ixabepilone), a microtubulin inhibitor for metastatic breast cancer.
ALLARITY THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics Oncology Pharmaceutical
Founded:
2004-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.allarity.com
Total Employee:
11+
Status:
Active
Contact:
401-426-4664
Email Addresses:
[email protected]
Total Funding:
18.5 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Content Delivery Network
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Bluebird Bio
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Halo Labs
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Repligen
Repligen is a biopharmaceutical company developing consumable products for the manufacture of biological drugs.
Current Employees Featured
Founder
Stock Details
Key Employee Changes
Official Site Inspections
http://www.allarity.com Semrush global rank: 4.95 M Semrush visits lastest month: 1.71 K
- Host name: 104.21.18.18
- IP address: 104.21.18.18
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Allarity Therapeutics"
Board of Directors - Allarity Therapeutics
Board of Directors Jerry McLaughlin Chairman, Independent Board Member Jerry McLaughlin has been a director of Allarity Therapeutics, Inc. since October 2022. Mr. McLaughlin has …See details»
Overview - Allarity Therapeutics
Mar 13, 2025 CLARITY IN CANCER CARE A FOCUSED PATH IN VALUE CREATION Corporate Overview Allarity Therapeutics is a clinical-stage precision medicine company …See details»
Allarity Therapeutics - Crunchbase Company Profile & Funding
Organization. Allarity Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Allarity Therapeutics is a …See details»
Allarity Therapeutics Announces Board Authorization of $5 Million …
Mar 3, 2025 Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was …See details»
Allarity Therapeutics, Inc. (ALLR) - Yahoo Finance Canada
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug …See details»
Allarity Therapeutics (ALLR) Company Profile & Description - Stock …
Mar 18, 2025 Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its …See details»
Allarity Therapeutics - Overview, News & Similar companies
May 14, 2024 Allarity Therapeutics is a late clinical-stage, precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for p atients with difficult-to-treat …See details»
Allarity Therapeutics Announces Presentation of Phase 2 Clinical …
Boston (March 17, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing …See details»
News - Allarity Therapeutics
Mar 6, 2025 News Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer Jun 25, 2024 Read more …See details»
Allarity Therapeutics Announces Board Authorization of $5
Mar 3, 2025 Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more …See details»
Biopharmaceutical Company Settles Charges for Disclosure Failures
March 12, 2025 - The Securities and Exchange Commission today announced settled charges against Massachusetts-based biopharmaceutical company Allarity Therapeutics, Inc. for …See details»
Allarity Therapeutics Launches Comprehensive Effort to Combat …
2 days ago Boston (March 24, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing …See details»
Allarity Therapeutics Inc, ALLR:NAQ profile - FT.com - Financial Times
Mar 18, 2025 Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of …See details»
Allarity Therapeutics A/S
Allarity Therapeutics A/S Venlighedsvej 1, DK-2970 Hoersholm CVR no. DK 28 10 63 51 Annual report for 2020 . Contents 2 Allarity Therapeutics A/S Company information etc. 3 …See details»
Allarity Therapeutics Announces Final Settlement with the U.S ...
Mar 13, 2025 Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more …See details»
Allarity Therapeutics (ALLR) Stock Price & Overview - Stock Analysis
5 days ago Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its …See details»
Allarity Therapeutics Strengthens Leadership with Key
Oct 3, 2024 In his new role at Allarity, Dr. Graff will continue to oversee the Company’s clinical development programs, including the advancement of its dual PARP and Tankyrase inhibitor, …See details»
Allarity Therapeutics Announces Final Settlement with the U.S ...
Boston (March 13, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing …See details»
Allarity Therapeutics, Inc. (ALLR) - Yahoo Finance
Find the latest Allarity Therapeutics, Inc. (ALLR) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Allarity Therapeutics Doses First Patient in Phase 1b
Mar 20, 2023 Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly developed companion diagnostic …See details»